Verastem (NASDAQ:VSTM) Rating Lowered to Strong Sell at Wall Street Zen

Verastem logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Verastem from “sell” to “strong sell,” though analyst sentiment overall remains “Moderate Buy,” with 11 Buy ratings, one Sell rating, and a consensus price target of $16.83.
  • Verastem reported a quarterly loss of $0.74 per share, missing the consensus estimate of a $0.47 loss; revenue of $24.01 million also fell short of expectations.
  • Shares opened at $6.33, while CEO Dan Paterson sold 44,121 shares at an average price of $8 under a pre-arranged trading plan.
  • MarketBeat previews top five stocks to own in December.

Verastem (NASDAQ:VSTM - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts have also recently issued reports about the company. Wolfe Research began coverage on Verastem in a research report on Thursday, September 17th. They issued an "outperform" rating on the stock. Royal Bank Of Canada cut their price target on Verastem from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, November 6th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Verastem in a research report on Monday, September 28th. Guggenheim set a $12.00 price objective on shares of Verastem and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, BTIG Research increased their price objective on shares of Verastem from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.83.

View Our Latest Stock Analysis on VSTM

Verastem Price Performance

Shares of VSTM opened at $6.33 on Friday. The firm has a market cap of $797.77 million, a PE ratio of -3.09 and a beta of 0.45. The company has a current ratio of 1.93, a quick ratio of 1.91 and a debt-to-equity ratio of 11.19. The firm has a fifty day simple moving average of $8.41 and a two-hundred day simple moving average of $6.32. Verastem has a 1-year low of $3.43 and a 1-year high of $10.82.

Verastem (NASDAQ:VSTM - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.27). The firm had revenue of $24.01 million during the quarter, compared to analysts' expectations of $26.57 million. Verastem had a negative return on equity of 359.49% and a negative net margin of 178.38%. On average, equities analysts anticipate that Verastem will post -1.88 EPS for the current year.

Insider Activity at Verastem

In other news, CEO Dan Paterson sold 44,121 shares of the company's stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $8.00, for a total value of $352,968.00. Following the completion of the sale, the chief executive officer directly owned 652,712 shares in the company, valued at $5,221,696. This represents a 6.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 48,041 shares of company stock valued at $386,390. Corporate insiders own 1.94% of the company's stock.

Hedge Funds Weigh In On Verastem

Institutional investors and hedge funds have recently bought and sold shares of the stock. New York State Common Retirement Fund grew its stake in shares of Verastem by 432.7% during the 3rd quarter. New York State Common Retirement Fund now owns 27,700 shares of the biopharmaceutical company's stock valued at $223,000 after acquiring an additional 22,500 shares during the period. Aquatic Capital Management LLC bought a new stake in Verastem during the 3rd quarter worth approximately $455,000. Entropy Technologies LP bought a new stake in Verastem during the 3rd quarter worth approximately $565,000. FORA Capital LLC bought a new stake in Verastem during the 3rd quarter worth approximately $88,000. Finally, Russell Investments Group Ltd. lifted its holdings in Verastem by 92.2% during the third quarter. Russell Investments Group Ltd. now owns 56,851 shares of the biopharmaceutical company's stock valued at $458,000 after purchasing an additional 27,273 shares in the last quarter. 88.37% of the stock is currently owned by hedge funds and other institutional investors.

About Verastem

(Get Free Report)

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer. Its research has centered on signaling pathways involved in tumor growth, including the RAS/MAPK pathway. The company's product, AVMAPKI FAKZYNJA CO-PACK, combines avutometinib and defactinib. The U.S. Food and Drug Administration approved the combination for certain adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy. Verastem is based in Needham, Massachusetts, and also develops investigational cancer therapies, including potential uses of avutometinib in combination with other medicines.

Featured Articles

Analyst Recommendations for Verastem (NASDAQ:VSTM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Verastem Right Now?

Before you consider Verastem, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.

While Verastem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines